| Literature DB >> 33824665 |
Kangkang Zha1,2,3, Zhiqiang Sun1,2,3, Yu Yang4, Mingxue Chen5, Cangjiang Gao1,2,3, Liwei Fu1,2,3, Hao Li1,2,3, Xiang Sui2, Quanyi Guo2, Shuyun Liu2.
Abstract
Articular cartilage is susceptible to damage, but its self-repair is hindered by its avascular nature. Traditional treatment methods are not able to achieve satisfactory repair effects, and the development of tissue engineering techniques has shed new light on cartilage regeneration. Mesenchymal stem cells (MSCs) are one of the most commonly used seed cells in cartilage tissue engineering. However, MSCs tend to lose their multipotency, and the composition and structure of cartilage-like tissues formed by MSCs are far from those of native cartilage. Thus, there is an urgent need to develop strategies that promote MSC chondrogenic differentiation to give rise to durable and phenotypically correct regenerated cartilage. This review provides an overview of recent advances in enhancement strategies for MSC chondrogenic differentiation, including optimization of bioactive factors, culture conditions, cell type selection, coculture, gene editing, scaffolds, and physical stimulation. This review will aid the further understanding of the MSC chondrogenic differentiation process and enable improvement of MSC-based cartilage tissue engineering.Entities:
Year: 2021 PMID: 33824665 PMCID: PMC8007380 DOI: 10.1155/2021/8830834
Source DB: PubMed Journal: Stem Cells Int Impact factor: 5.443
Effects of different bioactive factors on MSC chondrogenic differentiation.
| Bioactive factors | Cell type | Signaling pathway | Dose | Effect | Ref. |
|---|---|---|---|---|---|
| TGF- | Human BMSCs | Activate TGF- | 10 ng/mL | Promote MSC chondrogenic differentiation | [ |
| TGF- | Rat SDSCs | Activate RhoA/ROCK pathway and Smad pathway | 10 ng/mL | Induce gene expression of | [ |
| Human BMSCs | Activate MAPK pathway and Wnt pathway | 10 ng/mL | Induce gene expression of | [ | |
| BMPs | Human ADSCs and BMSCs | NA | 500 ng/mL | BMP-2, BMP-4, BMP-6, and BMP-7 are effective enhancers of MSC chondrogenic differentiation | [ |
| FGF-2 | Human BMSCs | NA | 10 ng/mL | Increase GAG/DNA content | [ |
| TSP-2 | Human UCBSCs | Activate Notch pathway | NA | Promote the chondrogenic differentiation of MSCs and attenuate their hypertrophic differentiation | [ |
| KGN | Human ADSCs | NA | 100 nM/L | Promote chondrogenic differentiation and suppress chondrocyte hypertrophy in MSCs | [ |
| Human SDSCs | Activate BMP-7/Smad5 pathway | 1 | Increase gene expression of | [ | |
| Human UCMSCs | Activate JNK/RUNX1 pathway and suppress | 1 | Elevate accumulation of extracellular matrix and chondrogenic gene expression of | [ | |
| Human BMSCs | NA | 100 nM/L | Increase gene expression of | [ | |
| Melatonin | Human BMSCs | Attenuate IL-1 | 50 nM/L | Save IL-1 | [ |
| Human BMSCs | NA | 50 nM/L | Enhance accumulation of GAG, COL II, and COL X | [ | |
| CS | Goat BMSCs | NA | CS-based hydrogels | Promote MSC chondrogenic differentiation and inhibit chondrocyte hypertrophy | [ |
| Ghrelin | Rat BMSCs | Enhance phosphorylation of ERK1/2 and DMNT3A | 10 nM/L | Upregulate expression of | [ |
| Atractylenolides | Rat BMSCs | Activate SHH pathway | 30 | Increase gene expression of | [ |
| FSTL-1 | Mouse MSCs | Activate TGF- | 5 | Upregulate expression of | [ |
TGF-β: transforming growth factor beta; BMSCs: bone marrow-derived mesenchymal stem cells; MSCs: mesenchymal stem cells; SDSCs: synovial membrane-derived mesenchymal stem cells; BMPs: bone morphogenetic proteins; ADSCs: adipose tissue-derived mesenchymal stem cells; NA: not applicable; FGF-2: fibroblast growth factor-2; GAG: glycosaminoglycan; TSP-2: thrombospondin-2; UCBSCs: umbilical cord blood-derived mesenchymal stem cells: KGN: kartogenin; UCMSCs: umbilical cord-derived mesenchymal stem cells; COL II: type II collagen; COL X: type X collagen; CS: chondroitin sulfate; FSTL-1: follistatin-like protein-1.
Effects of different physical stimulation on MSC chondrogenic differentiation.
| Physical stimuli | Cell type | Mechanism | Manner | Effect | Ref. |
|---|---|---|---|---|---|
| Vibration | Rat BMSCs | Activate Wnt/ | Low-magnitude (0.49 g) and high-frequency (40 Hz) vibration (30 min/day, 21 days) | Promote MSC chondrogenic differentiation and inhibit hypertrophic differentiation | [ |
| Tensile | Rabbit BMSCs | NA | Cyclic dynamic square wave tensile at 5, 10, 15, and 20% of strain, 0.5 Hz (4 h/day, 10 days) | Improve chondrogenic phenotype of MSCs | [ |
| Compression | Human BMSCs | Activate TGF- | Cyclic dynamic compression force at 5% of strain, 1 Hz (2 h/day, 21days) | Enhance MSC chondrogenic differentiation and suppress chondrocyte hypertrophy | [ |
| Rabbit BMSCs | NA | Cyclic dynamic compression force at 10% of Strain, 1 Hz (2 h/day, 21 days) | Enhance MSC chondrogenic differentiation and suppress chondrocyte hypertrophy and fibrocartilage formation | [ | |
| Microgravity | Rabbit BMSCs | Suppress IHH and SHH pathways | Rotation at 12–14 rpm for 21 days | Enhance chondrogenic differentiation and attenuate chondrocyte hypertrophy and aging of MSCs | [ |
| LIPUS | C3H10T1/2 cells | NA | LIPUS at 30 mW/cm2, 1 MHz with a pulse duration of 200 | Increase the expression of | [ |
| Rat BMSCs | Inhibit cell autophagy | LIPUS at 50 mW/cm2, on–off ratio of 20%, and irradiated with 3 MHz for 20 min (once a day, 10 days) | Increase cartilage-like ECM accumulation and gene expression of | [ | |
| Rabbit BMSCs | NA | MSC-seeded PGA scaffold was subcutaneously implanted into mouse and treated with LIPUS at 200 mW/cm2, 0.8 Hz (10 min/day, 4 weeks) | Increase collagen and GAG content and mechanical properties of the scaffold | [ | |
| Electric field | Human ADSCs | NA | Electric field at 20 mv/cm, 1 kHz (20 min/day, 7 days) | Increase gene expression of | [ |
| Mouse BMSCs | Activate P2X4, TGF- | Electrical field at 5 V/cm, 5.0 Hz with a duration of 8 ms for 3 days | Increase gene expression of | [ | |
| Swine BMSCs | Downregulate the expression of DMMT1 and increase methylation of the promoters of OCT4 and NANOG | Nanosecond pulsed electrical field of 10 ns at 20 kV/cm or 100 ns at 10 kV/cm, 1 Hz for 14 days | Enhance cartilaginous ECM accumulation and gene expression of | [ | |
| Electromagnetic field | Human BMSCs | NA | Electromagnetic field at 5 mT, 15 Hz (45 min/8 h, 21 days) | Increase gene expression of | [ |
| Human BMSCs | Stimulate calcium influx | Electromagnetic field at 2 mT, 15 Hz for 10 min once on day 1 induction | Enhance cartilaginous ECM deposition and gene expression of | [ |
BMSCs: bone marrow-derived mesenchymal stem cells; MSCs: mesenchymal stem cells; NA: not applicable; LIPUS: low-intensity pulsed ultrasound; ECM: extracellular matrix; PGA: polyglycolic acid; ADSCs: adipose tissue-derived mesenchymal stem cells; COL II: type II collagen; GAG: glycosaminoglycan.
Figure 1Chondrogenic differentiation process of mesenchymal stem cells (MSCs). The chondrogenic differentiation of MSCs is proposed to follow an endochondral ossification procedure, which includes five main stages: condensation, differentiation, proliferation, hypertrophy, and angiogenesis.
Figure 2Approaches for enhancing MSC chondrogenic differentiation. Several methods have proven to be effective in promoting chondrogenic differentiation of MSCs, including optimization of bioactive factors, culture conditions, cell type selection, coculture, gene editing, scaffolds, and physical stimulation.